A discrete cluster of urinary biomarkers discriminates between active systemic lupus erythematosus patients with and without glomerulonephritis
Authors:
- Carolina Landolt-MarticorenaCLCarolina Landolt-Marticorena
- Stephenie D. ProkopecSPStephenie D. Prokopec
- Stacey MorrisonSMStacey Morrison
- Babak NoamaniBNBabak Noamani
- Dennisse BonillaDBDennisse Bonilla
- Heather ReichHRHeather Reich
- James ScholeyJSJames Scholey
- Carmen Avila-CasadoCACarmen Avila-Casado
- Paul R. FortinPFPaul R. Fortin
- Paul C. BoutrosPBPaul C. Boutros
- Joan WitherJWJoan Wither
Open Access
- 4 October 2016
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 18 (1) , 1-12
Abstract
Management of lupus nephritis (LN) would be greatly aided by the discovery of biomarkers that accurately reflect changes in disease activity. Here, we used a proteomics approach to identify potential urinary biomarkers associated with LN. Urine was obtained from 60 LN patients with paired renal biopsies, 25 active non-LN SLE patients, and 24 healthy controls. Using Luminex, 128 analytes were quantified and normalized to urinary creatinine levels. Data were analyzed by linear modeling and non-parametric statistics, with corrections for multiple comparisons. A second cohort of 33 active LN, 16 active non-LN, and 30 remission LN SLE patients was used to validate the results. Forty-four analytes were identified that were significantly increased in active LN as compared to active non-LN. This included a number of unique proteins (e.g., TIMP-1, PAI-1, PF4, vWF, and IL-15) as well as known candidate LN biomarkers (e.g., adiponectin, sVCAM-1, and IL-6), that differed markedly (>4-fold) between active LN and non-LN, all of which were confirmed in the validation cohort and normalized in remission LN patients. These proteins demonstrated an enhanced ability to discriminate between active LN and non-LN patients over several previously reported biomarkers. Ten proteins were found to significantly correlate with the activity score on renal biopsy, eight of which strongly discriminated between active proliferative and non-proliferative/chronic renal lesions. A number of promising urinary biomarkers that correlate with the presence of active renal disease and/or renal biopsy changes were identified and appear to outperform many of the existing proposed biomarkers.Keywords
Funding Information
- Canadian Institutes of Health Research (QNT #78341)
- Alliance for Lupus Research
This publication has 51 references indexed in Scilit:
- Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritisArthritis Research & Therapy, 2012
- Urinary TWEAK Level as a Marker of Lupus Nephritis Activity in 46 CasesJournal of Biomedicine and Biotechnology, 2012
- Urinary Vascular Cell Adhesion Molecule, But Not Neutrophil Gelatinase-associated Lipocalin, Is Associated with Lupus NephritisThe Journal of Rheumatology, 2012
- VennDiagram: a package for the generation of highly-customizable Venn and Euler diagrams in RBMC Bioinformatics, 2011
- Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritisRheumatology, 2010
- Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort studyArthritis Research & Therapy, 2009
- Neutrophil gelatinase–associated lipocalin is a predictor of the course of global and renal childhood‐onset systemic lupus erythematosus disease activityArthritis & Rheumatism, 2009
- Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray ExperimentsStatistical Applications in Genetics and Molecular Biology, 2004
- Statistical significance for genomewide studiesProceedings of the National Academy of Sciences of the United States of America, 2003
- Induction of plasminogen activator inhibitor type 1 in murine lupus-like glomerulonephritisKidney International, 1995